RISEDRONATE-DRLA risedronate sodium 5 mg tablets blister pack

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

risedronate sodium, Quantity: 5 mg

Disponibbli minn:

Dr Reddys Laboratories Australia Pty Ltd

INN (Isem Internazzjonali):

Risedronate sodium

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: microcrystalline cellulose; povidone; lactose monohydrate; magnesium stearate; crospovidone; titanium dioxide; hypromellose; macrogol 8000; hyprolose; colloidal anhydrous silica; iron oxide yellow; iron oxide red; macrogol 400

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

7, 14, 28, 84

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

? Treatment of osteoporosis ,? Treatment of glucocorticoid-induced osteoporosis ,? Preservation of bone mineral density in patients on long term corticosteroid therapy

Sommarju tal-prodott:

Visual Identification: Yellow,film coated,round,biconvex tablets,debossed with R5 on one side,plain on the other side; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2012-10-03